Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: tonyt who wrote (925)	11/4/1997 12:39:00 AM
From: D.Right	Read Replies (3) \| Respond to of 2173

Dear Tony: Look like AMLN is actively pursuing an oral form of amylin. It would be nice of course if it is available sometime in the future. However, today WLA's Resulin got some kind of liver problem, which shows that although the peptide has its limits in drug delivery, small molecules have more uncertainty in potential side effects. That is why pramlintide as a "hormone replacement" for a long term drug has a huge advantage vs those "add on" drugs. People would appreciate this more as the Resulin story unfolds in the future. Good night D.Right